图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
免疫学评论综述™
影响因子: 1.404 5年影响因子: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN 打印: 1040-8401
ISSN 在线: 2162-6472

免疫学评论综述™

DOI: 10.1615/CritRevImmunol.2018026850
pages 415-431

Role of IL-10 Receptor Signaling in the Function of CD4+ T-Regulatory Type 1 cells: T-Cell Therapy in Patients with Inflammatory Bowel Disease

Shiwa Soukou
Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Leonie Brockmann
Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
Tanja Bedke
Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Nicola Gagliani
Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden
Richard A. Flavell
Department of Immunobiology, School of Medicine, Yale University, New Haven, 06520, USA; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Samuel Huber
Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

ABSTRACT

Inflammatory bowel disease (IBD) is caused by the interplay of various factors. It occurs in genetically susceptible people due to dysregulated immune responses to several unknown antigens, including those derived from the commensal microbiota. Effector T-helper cells, especially TH17 cells, are considered a major driver of disease progression. The endogenous resident counterparts of effector T-helper cells are the regulatory T cells, mainly Foxp3+ Treg cells and type 1 regulatory (TR1) T cells. Both have strong immune regulatory capacity and can terminate immune responses. Interestingly, the expression of IL-10 receptor on regulatory T cells has a high impact on the regulatory capacity of these cells. Inflammatory bowel disease is becoming a global health issue. No curative therapy is currently available. However, initial clinical trials have been conducted successfully, proving the safety of a regulatory T-cell–based therapy. This therapy might lead to long-lasting remission and to a possible cure for IBD. This review provides a summary of the current findings and the outcome of the clinical trials based on T-cell therapy for IBD and for other inflammatory conditions.


Articles with similar content:

How Can the Innate Immune System Influence Autoimmunity in Type 1 Diabetes and Other Autoimmune Disorders?
Critical Reviews™ in Immunology, Vol.25, 2005, issue 3
L. Wen, F. S. Wong
CD8+ Memory T Lymphocytes from Bone Marrow— Immune Function and Therapeutic Potential
Critical Reviews™ in Immunology, Vol.27, 2007, issue 6
Xiaoyu Zhang, Donna L. Farber, Scott E. Strome, Aaron H. D. Wood
A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Jacques Galipeau, Moutih Rafei
Mechanisms of Cholera Toxin in the Modulation of TH17 Responses
Critical Reviews™ in Immunology, Vol.35, 2015, issue 2
Hsing-Chuan Tsai, Reen Wu
Immunopathogenesis of the Anti-Synthetase Syndrome
Critical Reviews™ in Immunology, Vol.38, 2018, issue 4
Yurdagül Uzunhan, Baptiste Hervier, Vincent Vieillard, Catherine Gayed, Isabelle Cremer